Phase 3 Miss—Or Strategic Pivot? Renibus’ RBT-1 Data Tells a More Nuanced Story

Most Phase 3 failures are blunt. This one isn’t. Renibus Therapeutics just reported results from its PROTECT trial—and while the headline says “missed primary endpoint,” the underlying signal is more complicated.

The Setup: Can You Prevent Surgical Complications Before They Start?

The drug in focus: RBT-1 What it aims to do:

• Act as a pharmacologic preconditioning agent
• Reduce inflammation and oxidative stress
• Protect organs before cardiac surgery happens

The idea is elegant: Instead of treating complications, prevent them upstream.

The Trial Design (Solid on Paper)

The Phase 3 PROTECT trial checked most of the right boxes:

• 433 patients
• 34 sites across the U.S. and Canada
• Randomized, double-blind, placebo-controlled
• Patients undergoing:
  • Coronary artery bypass grafting (CABG)
  • Valve surgery
• Single infusion 24–48 hours pre-surgery
• Follow-up through 60 days post-op

This is a well-constructed, late-stage study.

The Outcome: Primary Endpoint Missed

Let’s be clear: The trial did not meet its primary endpoint.

• Composite endpoint (win ratio): 0.87
• p-value: 0.33 (not statistically significant)

The endpoint included:

• Death
• Dialysis-requiring acute kidney injury
• 30-day readmissions
• ICU duration

No statistical separation = no approval pathway (for now).

So What Went Wrong?

Here’s the critical detail most headlines miss: The patients were too low-risk.

• ~70% had <2% predicted mortality risk (based on the STS risk calculator)

That creates a classic problem: If patients are unlikely to have complications anyway, you can’t prove your drug prevents them.

This is less about drug failure, and more about trial design vs. population selection.

The Signal: High-Risk Patients Tell a Different Story

Post-hoc analyses showed something interesting:

• Patients with chronic kidney disease (CKD)
• Patients with higher surgical risk scores

…appeared to benefit more from RBT-1.

This is not definitive proof. But it’s directionally important.

CEO Jeffrey Keyser put it plainly:

• The biology still holds
• The signal exists—just not in everyone

Safety Profile: Quietly a Win

One thing that did work: Safety

• Generally well-tolerated
• Mild adverse events:
  • Photosensitivity
  • Infusion-related reactions
• No surgery delays or cancellations

In perioperative settings, that last point matters a lot. A drug that complicates surgery is dead on arrival. RBT-1 clears that bar.

External Validation: Clinicians See Potential

Michael E. Jessen from UT Southwestern highlighted:

• Post-op complications remain a major unmet need
• Signals in high-risk patients are clinically relevant
• Further targeted studies are justified

Translation: Don’t abandon this. Refocus it.

Bigger Pattern: The “Wrong Population” Problem in Pharma

This isn’t new. Many drugs fail Phase 3 not because they don’t work—but because:

• The effect size is diluted
• The patient pool is too broad

Precision medicine flips this:

• Smaller population
• Stronger effect
• Higher probability of success

That’s likely where RBT-1 is heading.

What Happens Next?

Renibus is already signaling the pivot:

• Reanalyze data
• Identify risk-enriched populations
• Design more targeted trials

RBT-1 also has:

• Breakthrough designation
• Fast Track status from the U.S. Food and Drug Administration

That gives regulatory flexibility—if the signal strengthens.

The Devil’s Protocol: Let’s Stress-Test This

Best-case scenario:

• Clear benefit in high-risk cardiac patients
• Smaller, targeted trial succeeds
• RBT-1 becomes a niche but valuable perioperative therapy

Worst-case scenario:

• Post-hoc signals don’t replicate
• Effect size too small even in high-risk groups
• Program quietly shelved

Most likely:

• One more targeted study decides everything

Bottom Line

This is not a clean win. But it’s not a clean loss either. Renibus Therapeutics has:

• A safe drug
• A missed endpoint
• A potentially salvageable signal

The next move is obvious—and risky: Go narrower. Go higher-risk. Prove it works where it matters most. Because in pharma, who you treat is often more important than what you give them.